Philip Morris International Inc.

Philip Morris International Inc. (PM) Market Cap

Philip Morris International Inc. has a market capitalization of .

No quote data available.

CEO: Jacek Olczak

Sector: Consumer Defensive

Industry: Tobacco

IPO Date: 2008-03-17

Website: https://www.pmi.com

Philip Morris International Inc. (PM) - Company Information

Market Cap: -|Sector: Consumer Defensive

Company Profile

Philip Morris International Inc. functions as a prominent tobacco enterprise, actively working toward a smoke-free future. The company is strategically diversifying its long-term product range to incorporate items beyond traditional tobacco and nicotine. Its primary business involves both conventional cigarettes and an expanding array of smoke-free alternatives, such as innovative heat-not-burn devices, vapor products, and oral nicotine solutions. These offerings are distributed in markets worldwide, with the exception of the United States. The smoke-free portfolio includes brands like HEETS (encompassing Creations, Dimensions, Marlboro variants), Parliament HeatSticks, and TEREA, in addition to KT&G-licensed brands Fiit and Miix. For conventional cigarettes, the company sells internationally recognized brands such as Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris. Regionally, it also owns major cigarette brands like Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia, and Fortune and Jackpot in the Philippines. PMI's smoke-free innovations are currently available across 71 global markets. Established in 1987, Philip Morris International Inc. is headquartered in New York, New York.

Analyst Sentiment

75%
Strong Buy

From 17 Active Polls

1Y Forecast: $210.50

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$182

Median

$215

High Bound

$225

Average

$211

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$210.50
▲ +10.31% Upside
Low Target
$182.00
-5% Risk
Median Target
$215.00
13% Mid
High Target
$225.00
18% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PHILIP MORRIS INTERNATIONAL INC (PM) — Investment Overview

🧩 Business Model Overview

Philip Morris International (PM) manufactures and sells nicotine products through a global distribution network, earning revenue primarily from the sale of cigarettes and smoke-free alternatives (notably heated tobacco products). The economics are driven by a blend of (1) device-and-consumable style recurring purchasing for smoke-free formats and (2) established, high-volume cigarette routes to market.

A key structural feature is consumer persistence: once adult consumers adopt a specific product category (and, for heated tobacco, a device ecosystem), the ongoing need to purchase consumable units creates a durable demand base. That stickiness is reinforced by PM’s scale in manufacturing, logistics, and marketing/retailer execution within regulated adult-use channels.

💰 Revenue Streams & Monetisation Model

  • Cigarettes (core volume engine): Transactional purchases with mature demand, monetised through pricing, mix, and effective excise pass-through where allowed.
  • Heated tobacco (device ecosystem + consumables): More “repeat-like” economics versus cigarettes because consumables must be replenished, supporting steadier long-run volume stability when adoption holds.
  • Other nicotine products: Supplementary offerings that can help broaden the portfolio as regulation and consumer preferences evolve.

Margin drivers typically include: (i) product and geography mix (including the relative contribution of smoke-free versus cigarettes), (ii) manufacturing cost discipline and scale benefits, (iii) procurement leverage across tobacco and indirect inputs, and (iv) the regulatory treatment of different formats—especially excise/tax differentials and marketing restrictions.

🧠 Competitive Advantages & Market Positioning

PM’s competitive position rests on moats that are less about “innovation narratives” and more about execution under tight regulation and a consumer-category adoption dynamic.

  • Switching costs (within product ecosystems): Adoption of heated tobacco ties consumers to consumable formats and often to specific devices. While regulation and competition can influence transitions, the ecosystem structure tends to slow consumer churn versus switching between unrelated categories.
  • Regulatory and compliance moat (high barrier to entry): Tobacco products operate in a fragmented, jurisdiction-specific regulatory environment. PM’s capability in product stewardship, approvals, and ongoing compliance reduces the likelihood of prolonged disruption relative to smaller or less-experienced peers.
  • Scale cost advantages: Large-scale manufacturing, procurement, and logistics support lower unit costs and resilience during excise/tax changes and volume pressures.
  • Intangible assets (portfolio expertise): The company’s accumulated know-how in operating regulated adult-use markets—supply chain planning, demand forecasting, and retailer execution—supports steadier commercialization of category shifts.

COMPETITIVE BENCHMARKING:

  • British American Tobacco (BAT): Major global peer competing in cigarettes and smoke-free products, with its own heated tobacco and vapour strategy.
  • Japan Tobacco International (JTI): Competes strongly in heated tobacco formats and markets with different regulatory constraints.
  • Imperial Brands: Competes across cigarettes and reduced-risk offerings, often with a different geography mix and regulatory exposure profile.

Contrast in industry focus: PM is primarily oriented toward heated tobacco adoption at scale in international markets, positioning its portfolio around regulatory pathways for reduced-risk products while maintaining cigarettes as the cash-generating base. This contrasts with peers whose reduced-risk mixes may be more weighted toward vapour or other categories depending on country rules and product approvals.

🚀 Multi-Year Growth Drivers

  • Smoke-free category shift: Over a 5–10 year horizon, total market growth is less about expanding nicotine users and more about migration within nicotine consumption—from cigarettes toward alternatives where permitted and where adults find acceptable utility.
  • Regulatory-defined “winners” within reduced-risk categories: Jurisdictions that sustain differentiated treatment (tax and marketing rules) for approved smoke-free formats can support adoption economics and help preserve category momentum.
  • Operating leverage and cost discipline: Scale manufacturing and procurement can help protect cash generation even if unit volumes face pressure.
  • Portfolio resilience across geographies: Diversification across multiple markets can smooth volatility in local excise schedules, enforcement intensity, and consumer response.

The investment case is best framed as a cash-flow durability story plus a managed transition: maintain mature-cash engines while scaling reduced-risk formats where regulatory frameworks and consumer acceptance support sustainable unit economics.

⚠ Risk Factors to Monitor

  • Regulatory reversals and excise parity: Policies that reduce or eliminate differential treatment of smoke-free products can compress unit economics and slow adoption.
  • Technological and consumer preference shifts: Increased share movement toward alternative nicotine technologies (e.g., other reduced-risk categories) can undermine the expected transition profile.
  • Litigation and health-policy outcomes: Legal exposure and evolving regulatory standards can create cost and uncertainty around product marketing and health claims.
  • Illicit trade and enforcement gaps: Counterfeit or untaxed product inflows can pressure pricing and volumes, especially in jurisdictions with weaker controls.
  • Capital intensity and execution risk: Device and product ecosystem scale-up requires disciplined working capital management and supply chain continuity.

📊 Valuation & Market View

Tobacco equities are typically valued on cash-flow durability and the credibility of capital returns rather than rapid top-line growth. Market pricing often reflects:

  • Free cash flow conversion: Sustained conversion supports dividends and share repurchases.
  • Multiple sensitivity to regulatory risk: When markets perceive rising regulatory uncertainty, equity valuations commonly compress; clearer policy pathways can support higher confidence in cash flows.
  • Mix and margin expectations: The expected trajectory of smoke-free versus cigarettes influences earnings quality and long-term margins.

In practice, investors often triangulate between EV/EBITDA (for operating stability), free-cash-flow yield (for capital return capacity), and earnings resilience under excise and regulatory scenarios.

🔍 Investment Takeaway

PM’s long-term thesis centers on durable cash generation from cigarettes combined with a regulated, ecosystem-based approach to smoke-free growth. The core moats—scale cost advantages, ecosystem switching dynamics in heated tobacco, and a regulatory/compliance capability that lowers execution risk—support resilience through industry transitions, provided that excise treatment and reduced-risk regulatory pathways remain navigable.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"PM reported Q2 2026 revenue of $11.19B and net income of $2.82B (EPS $1.80) with margins remaining strong. QoQ, revenue rose from $10.15B (Q1 2026) by +10.3%, while net income increased from $2.44B by +15.6%. YoY, revenue increased from $10.14B in Q2 2025 by +10.3%, and net income improved from $3.04B by -7.3% (net income down despite revenue growth). Profitability was mixed over the last four quarters: gross margin expanded vs Q4 2025 (68.4% in Q2 2026 vs 65.6% in Q4 2025), but net margin compressed compared with Q3 2025 (25.2% in Q2 2026 vs 32.1% in Q3 2025). Operating income increased QoQ to $4.53B (operating margin 40.5%), but YoY profitability declined as the prior-year quarter had unusually high net margin. Cash flow quality improved QoQ: operating cash flow swung from -$0.40B in Q1 2026 to +$5.13B in Q2 2026, lifting free cash flow to $4.75B (after ~$0.38B capex). Shareholder returns appear resilient given PM’s regular dividends: dividends paid were ~$2.30B in the quarter, supporting payout ratio of ~81.5%. Balance sheet leverage remains heavy with total debt ~$49.1B and negative total equity (-$6.66B), though the company still generated significant cash flow. Total shareholder return is currently modest on price action (1y_change -1.68%, no momentum boost) with dividend yield ~0.81%. Analyst valuation looks optimistic vs consensus price target (~$207 vs $158), implying potential upside if margins stabilize."

Revenue Growth

Positive

Revenue grew +10.3% QoQ (Q1 2026 $10.15B to Q2 2026 $11.19B) and +10.3% YoY (Q2 2025 $10.14B to Q2 2026 $11.19B), showing consistent top-line strength.

Profitability

Neutral

Operating margin improved QoQ (38.4% in Q1 2026 to 40.5% in Q2 2026). However, YoY net income declined (-7.3%) and net margin is below Q3 2025 (25.2% vs 32.1%), indicating some profitability normalization.

Cash Flow Quality

Positive

Operating cash flow rebounded sharply to +$5.13B QoQ (from -$0.40B). Free cash flow was strong at $4.75B, and dividends of ~$2.30B were covered by FCF (payout ratio ~81.5% this quarter).

Leverage & Balance Sheet

Caution

Balance sheet remains leveraged: total assets ~ $68.3B, total debt ~$49.1B, and total equity is negative (-$6.66B). Equity deteriorated vs Q1 2026 (-$7.30B to -$6.66B improved slightly), but leverage/risk profile remains elevated.

Shareholder Returns

Neutral

Dividend yield is ~0.81% with meaningful cash outlays (~$2.30B/quarter). Price performance has been weak over 1 year (-1.68%), so total return is likely modest; no >20% momentum tailwind.

Analyst Sentiment & Valuation

Positive

Consensus target (~$207) is above the current price ($157.79), suggesting valuation upside if profitability stabilizes; however, without price momentum, re-rating may depend on margin/cash flow consistency.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

PM delivered strong Q2 and maintained full-year guidance after better-than-expected H1 execution. Organic Q2 net revenue rose +7.6% and adjusted diluted EPS reached $2.20 (+15% dollar terms), with outperformance partly driven by non-operational items ($0.03 favorable currency from deferred tax effects tied to the weaker Russian ruble) and partly by operational mix (SG&A phasing into Q3 and strong combustible performance). International smoke-free remains the profit engine: H1 gross margin expanded +190 bps to 70%, largely from IQOS momentum and VEEV contribution, while combustible pricing powered profitability (pricing +9.2% in H1). Guidance is intact primarily due to an improving U.S. setup: a broadened ZYN variant slate and the U.S. MRTP authorization enabling reduced-risk marketing claims, supported by the 'When it Clicks' campaign and intensified 2H investment. Key headwinds are Japan excise volatility in H2 and tough Q3 tax/finance comparisons.

AI IconGrowth Catalysts

  • International Smoke-Free Products strength: IQOS high single-digit IMS/volume growth plus double-digit top-line growth and gross margin expansion
  • E-vapor VEEV acceleration: +55% Q2 shipment growth and +72% H1 shipment growth; profitability progression
  • Combustible resilience: pricing strength (+9.2% in H1; ~+10% in Q2) supporting gross profit growth (+6.1% organic H1 for combustible; +8% Q2 for international combustible gross profit)
  • ZYN momentum and portfolio expansion: shipments +2% YoY to 2.9B pouches; early ZYN Ultra shipments to 9 mg and 11 mg variants with planned extensions

Business Development

  • Launches/rollouts of IQOS alternative heating technology (BONDS by IQOS) in Poland, Czech Republic, and Morocco
  • ZYN Ultra rollout in nine and 11 milligram moist variants; planned introduction of 1.5 milligram and eight milligram dry formats in Q3
  • IQOS market expansion: Q2 launch of IQOS in Malta (new regulatory framework established for smoke-free products)
  • Regulatory milestone for ZYN in the U.S.: modified risk tobacco product (MRTP) authorization for 20 SKUs enabling reduced-risk marketing claim

AI IconFinancial Highlights

  • Q2 organic net revenue: +7.6% (+10%+ in dollar terms); total quarterly net revenue over $11B for first time
  • Q2 adjusted diluted EPS: $2.20, +15% currency-neutral / +15% dollar terms; +14% currency-neutral progression; $0.03 favorable currency impact
  • EPS outperformance drivers vs prior forecast: ~one-third from unrealized transactional effect from deferred tax liability linked to weaker Russian ruble; remaining two-thirds from SG&A phasing (Q2 investments moved to Q3) and strong combustible performance
  • H1 gross margin expansion: +190 bps to 70% (international smoke-free core driver); H1 international gross margin expansion: +160 bps to 68.6%
  • H1 adjusted operating income margin: expanded +40 bps organically / +60 bps in dollar terms to ~42%; gross margin +70 bps driver; SG&A lower than expected in Q2 due to phasing but H1 margin -30 bps from higher YoY commercial investment
  • Full-year cigarette volume guidance reduced: expected decline ~2%-3% vs 3% previously; expectation of total shipment volume around stable to slightly positive (high single-digit smoke-free growth offset)

AI IconCapital Funding

  • No buyback/debt/cash runway figures provided in the transcript excerpt
  • Operating cash flow outlook: around $13.5B (implied funding flexibility for investment and shareholder returns)

AI IconStrategy & Ops

  • U.S. investment step-up decision: SG&A higher in 2H than previously anticipated due to strategic choice to accelerate U.S. growth investment
  • ZYN commercial plan: reduce promotional intensity vs prior periods in Q2 (supports close-to-flat YoY revenue with volume slightly up), while preparing for a broader 2H commercial push
  • Marketing campaign: major new brand campaign 'When it Clicks' rollout starting this month to build ZYN brand emotion and franchise
  • Supply/production note: ramp-up of new ZYN capacity in Colorado; full-scale commercial production began this month, contributing to higher manufacturing costs impacting YoY U.S. gross profit

AI IconMarket Outlook

  • Full-year 2026 guidance maintained: organic net revenue growth +5% to +7%; organic operating income growth +7% to +9%; currency-neutral adjusted diluted EPS growth +7.5% to +9.5%
  • Full-year EPS range (adjusted diluted): $8.26 to $8.41; currency tailwind around $0.15 at prevailing rates; equals +9.5% to +11.5% vs prior baseline
  • Full-year volume target: sixth consecutive year of total volume growth; total shipments stable to slightly positive; smoke-free high single-digit growth offsets cigarette decline
  • Q3 guidance: HTU shipment volume ~41B units vs Q3 2025 +15.5% growth; target mid-single-digit Q3 organic smoke-free net revenue and gross profit growth; target mid-single-digit Q3 overall organic top-line growth with modest margin expansion
  • Q3 adjusted diluted EPS target: $2.20 to $2.25, including unfavorable currency impact of $0.08; tax rate comparison noted as challenging vs Q3 last year

AI IconRisks & Headwinds

  • Japan excise-driven pricing volatility: April 1 excise increase required largest HTU price increase to date; Q2 IMS declined 3.4% after Q1 pantry loading reversal; additional excise-related volatility expected in H2 around October
  • EU flavor ban market implementation: ongoing final implementation headwinds referenced (Poland; also Hungary disruptions)
  • ZYN category competition and pricing premium: ZYN off-take broadly stable to slightly growing YoY in an uneven competitive landscape; category share impacted by competitive gaps in higher-strength segment (moist product / certain flavors) and elevated price premium (addressed via Ultra variants)
  • H2 comparison headwinds: net finance cost and effective tax rate comparisons described as challenging

Q&A: Analyst Interest

  • Guidance not revised despite strong H1: Management said full-year guidance remains unchanged because U.S. conditions are improving into an “exciting moment,” driven by a broader ZYN variant portfolio (including ZYN Ultra and additional strengths) plus the new 'When it Clicks' campaign. They emphasized capacity to accelerate investment while maintaining bottom-line optimization.
  • Promotional spend expectations behind ZYN: Management indicated Q2 featured reduced promotional activity versus expectations (supporting close-to-flat revenue YoY with slightly higher volume). For 2H, they would use “every lever” (marketing, POS, in-store execution) but declined to comment on specific price-action/promotion levels beyond noting ZYN will stay the leading premium brand.
  • ZYN Ultra rollout incremental impact and timeline: Management highlighted ZYN Ultra launch beginning with 9 mg and 11 mg moist variants at lower per-pouch prices to reduce premium versus the closest competitor. They said early consumer and retailer feedback is positive with rapid distribution build, and that further portfolio extensions (1.5 mg and 8 mg dry) are planned for Q3.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the PM Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Philip Morris International Inc. (PM) Financial Profile